重组人脑利钠肽治疗慢性心力衰竭的疗效及对患者白细胞介素―6水平的影响.docVIP

重组人脑利钠肽治疗慢性心力衰竭的疗效及对患者白细胞介素―6水平的影响 　　【摘要】 目的：探讨重组人脑利钠肽治疗慢性心力衰竭的疗效及对患者白细胞介素-6水平的影响。方法：选取2013年5月-2015年12月本院接收慢性心力衰竭患者98例，随机分配法将其分为对照组与观察组，每组各49例。对照组患者接受硝酸甘油治疗，观察组患者接受重组人脑利钠肽治疗，比较两组治疗效果及药物对患者白细胞介素-6水平的影响。结果：治疗后，两组患者的临床症状均得到明显缓解，对照组患者左室舒张末内径（LVEDD）、左室收缩末内径（LVESD）高于观察组，左室射血分数（LVEF）低于观察组，两组比较差异均有统计学意义（P0.05）。结论：重组人脑利钠肽治疗慢性心力衰竭患者效果显著，能够有效降低患者白细胞介素-6水平，值得推广应用。 　　【关键词】 慢性心力衰竭； 重组人脑利钠肽； 临床疗效； 白细胞介素-6 　　【Abstract】 Objective：To explore the efficacy and effect in interleukin-6 levels of Recombinant Human Brain Natriuretic Peptide in treatment of chronic heart failure patients. Method：The 98 patients with chronic heart failure in our hospital were selected from May 2013 to December 2015，according to the random allocation methods，they were divided into two groups，49 cases in each group.The control group received Nitroglycerin treatment，observation group received Recombinant Human Brain Natriuretic Peptide therapy，the therapeutic efficacy and effect in interleukin-6 levels of two groups were compared.Result：After treatment，the clinical symptoms of two groups were significantly alleviate，the left ventricular end diastolic diameter and left ventricular end systolic inner diameter of control group were higher than the observation group，left ventricular ejection fraction of control group was lower than the observation group，the differences were statistically significant（P0.05）.Conclusion：Recombinant Human Brain Natriuretic Peptide has a good effect in treatment of chronic heart failure， can effectively reduce the levels of interleukin 6，it is worthy of popularization and application. 　　【Key words】 Chronic heart failure； Recombinant Human Brain Natriuretic Peptide； Clinical efficacy； Interleukin-6 　　慢性心衰是临床常见的心血管疾病，近年来发病人数逐年上升，发病患者通常存在早期心脏疾病史、血流异常、全身性炎症等症状，继而造成心肌损伤，此外，长期吸烟、酗酒、情绪激动、过度劳累、不良饮食习惯等同样具有诱发慢性心衰的风险[1-2]。该病病程较长，患者发病初期无明显症状，不会影响患者的工作、生活，长期发展患者可能出现活动能力受限、局部水肿、呼吸困难等表现，患者发病时可能存在其他心脏问题，因此慢性心衰同样具有较高的致死、致残风险。目前临床对于该病的治疗重点逐渐侧重于如何降低患者的住院率及病死率，主要以病因治疗，控高血压、糖尿病等危险因素，并根据病情予以利尿药、硝酸酯及